BD Diagnostics launches BD Viper System in U.S.

BD Diagnostics, a part of Becton Dickinson and Company, announced on Tuesday that the U.S. Food and Drug Administration has cleared the launch of its BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay.

The BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay will be used in BD Diagnostic's BD Viper System with XTR Technology to detect T. vaginalis DNA in endocervical, vaginal and urine samples. The BD Viper System is used by laboratories to test samples for T. vaginalis, C. trachomatis and N. gonorrhea and can also be used in batch mode to test for chlamydia and gonorrhea, trichomonas and herpes.

"The global prevalence of trichomoniasis is on the rise and there are more asymptomatic cases than previously thought," Chris Demiris, the worldwide group marketing manager of BD Diagnostics, said. "The availability of an automated platform is especially important as clinical and public health communities embrace the need for a test that provides timely and accurate diagnosis of trichomoniasis when screening high-risk populations."

Trichomoniasis is one of the most common, and curable, sexually transmitted infections. There are more than 180 million cases of trichomoniasis around the world each year. Trichomoniasis is often asymptomatic and is capable of increasing a women's chance of HIV infection.